Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus BOTOX COSMETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus BOTOX COSMETIC.
ARDUAN vs BOTOX COSMETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein necessary for vesicle fusion, thereby causing temporary muscle paralysis.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
Intramuscular injection; glabellar lines: 20 units divided into 5 sites (4 units each); lateral canthal lines: 12 units per side divided into 3 sites (4 units each); forehead lines: 10-20 units divided into 4-8 sites. Repeat no more frequently than every 3 months.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
The terminal elimination half-life of botulinum toxin type A is approximately 10 hours (range 8-12 hours) following intramuscular injection. However, the clinical effect persists for months due to prolonged inhibition of acetylcholine release at the neuromuscular junction.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Botulinum toxin type A (BOTOX COSMETIC) is metabolized intracellularly by proteases. Renal elimination of inactive metabolites is <1% as intact toxin. Biliary/fecal excretion accounts for the majority of degraded byproducts, though exact percentages are not quantifiable due to rapid degradation.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker